Originally from Switzerland, Dr Dan Atar, MD is a 1985 graduate from Basel University Medical School. He subsequently trained in internal medicine and cardiology. This was followed by stays abroad: at John Hopkins University in Baltimore (1991–1994) and the University of Copenhagen, where he worked as a senior cardiologist. From 1997 to 1998 Dr Dan Atar served as a senior physician at the University Hospital of Zurich. He became a cardiology junior faculty member under the guidance of Professor Thomas F. Lüscher, MD. In addition to clinical work, Dr Atar conducted experiments, investigating ischaemia and reperfusion of the heart. After serving as a senior physician at the University of Copenhagen, he received a call in 2002 to a full professorship in cardiology at the University of Oslo, Norway, and was appointed the head of the cardiology department at Aker University Hospital in Oslo. Here he worked with a large team of cardiologists and clinical researchers, especially in the field of cardiac markers, heart failure, and cardiovascular pharmacology. He is currently Head of Research at Oslo University Hospital Ulleval, Dept. of Medicine, and holds a full Professorship in Cardiology at the University of Oslo along with a Visiting Associate Professorship at the Johns Hopkins University in Baltimore, Maryland, USA. Prof. Atar served as Chairman of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology and is Associate Editor of 'Cardiology' and 'The Heart Journal Cardiovascular Pharmacotherapy'.
He co-authored more than 350 scientific articles and a number of ESC guidelines, such as the 2012 STEMI guideline and 2010, 2012 and 2016 Atrial Fibrillation guideline. In 2016, he appeared on the prestigious Thompson-Reuters list of "The Most Cited Researchers of the World". Prof. Atar has been a member of Scientific Advisory Board at Serodus ASA since December 2015 and of ASAMEDIC since February 2016. For the last two years, he has served as Chairman of the Clinical Advisory Board at FIBREX Medical Inc., France.Back to speakers